Improvement of cardiac performance by AR-L 115 BS, a new cardiotonic drug, in the experimental failing dog heart.
The cardiotonic effect of AR-L 115 BS was assessed in 5 dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. AR-L 115 BS in doses of 1-60 mg improved cardiac function in a dose-dependent manner and at 30 and 60 mg improved it beyond control values. These doses of AR-L 115 BS, however, produced neither a significant increase in heart rate nor arrhythmias. The results indicate that the drug would be of use in the treatment of heart failure.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D013268:Stimulation, Chemical
D002316:Cardiotonic Agents; D007093:Imidazoles; D015105:3',5'-Cyclic-AMP Phosphodiesterases; C029758:sulmazole